272 related articles for article (PubMed ID: 17803594)
21. Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo.
Bladon J; Taylor P
J Clin Apher; 2002; 17(4):177-82. PubMed ID: 12494410
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis.
Knobler R; Duvic M; Querfeld C; Straus D; Horwitz S; Zain J; Foss F; Kuzel T; Campbell K; Geskin L
Photodermatol Photoimmunol Photomed; 2012 Oct; 28(5):250-7. PubMed ID: 22971190
[TBL] [Abstract][Full Text] [Related]
23. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma.
Knobler R; Jantschitsch C
Transfus Apher Sci; 2003 Feb; 28(1):81-9. PubMed ID: 12620272
[TBL] [Abstract][Full Text] [Related]
24. Extracorporeal photochemotherapy (ECP) in treatment of patients with c-GVHD and CTCL.
Gasová Z; Spísek R; Dolezalová L; Marinov I; Vítek A
Transfus Apher Sci; 2007 Apr; 36(2):149-58. PubMed ID: 17376742
[TBL] [Abstract][Full Text] [Related]
25. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
Seremet S; Abhyankar S; Herd TJ; Aires D
J Drugs Dermatol; 2016 Oct; 15(10):1212-1216. PubMed ID: 27741338
[TBL] [Abstract][Full Text] [Related]
26. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
[TBL] [Abstract][Full Text] [Related]
27. Retinal toxic reactions following photopheresis.
Vagace JM; Gervasini G; Morais F; Benitez J; Alonso N; de Argila D; Arranz I; Bajo R
Arch Dermatol; 2007 May; 143(5):622-5. PubMed ID: 17515512
[TBL] [Abstract][Full Text] [Related]
28. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
Lewis DJ; Duvic M
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28338261
[TBL] [Abstract][Full Text] [Related]
29. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.
Prinz B; Behrens W; Hölzle E; Plewig G
Arch Dermatol Res; 1995; 287(7):621-6. PubMed ID: 8534123
[TBL] [Abstract][Full Text] [Related]
30. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
31. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
32. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
33. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
34. Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
Schreiner T; Gaczkowski A; Scharffetter-Kochanek K; Borberg H
Transfus Apher Sci; 2005 Apr; 32(2):197-203. PubMed ID: 15784454
[TBL] [Abstract][Full Text] [Related]
35. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
Girardi M; Carlson K; Huang X; Corman SL; Edmundson P; Schmier J; Kale HP; Raina R; Foss F
J Dermatolog Treat; 2024 Dec; 35(1):2360568. PubMed ID: 38852942
[TBL] [Abstract][Full Text] [Related]
36. Extracorporeal photopheresis: a focus on apoptosis and cytokines.
Bladon J; Taylor PC
J Dermatol Sci; 2006 Aug; 43(2):85-94. PubMed ID: 16797926
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic approaches in cutaneous lymphoma.
Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
[TBL] [Abstract][Full Text] [Related]
38. Therapy options in cutaneous T-cell lymphoma.
Apisarnthanarax N; Duvic M
Expert Rev Anticancer Ther; 2001 Oct; 1(3):403-20. PubMed ID: 12113107
[TBL] [Abstract][Full Text] [Related]
39. Extracorporeal photopheresis: from solid organs to face transplantation.
Hivelin M; Siemionow M; Grimbert P; Lantieri L
Transpl Immunol; 2009 Jul; 21(3):117-28. PubMed ID: 19409991
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]